Therapeutics Announces Settlement of Legal Action with Laidlaw & Company

Therapeutics Announces Settlement of Legal Action with Laidlaw & Company

YORK, May 18 2017 - Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the

treatment of central nervous system (CNS) diseases, and Laidlaw & Company (UK) Ltd. ("Laidlaw"), today announced

final disposition of all claims and counterclaims in all legal proceedings related to Relmada Therapeutics, Inc. v. Laidlaw

& Company (UK) Ltd., et al., Case No.1:16-CV-07767, pending in the United States District Court for the Southern District

the terms of the settlement, Relmada Therapeutics hereby releases all Released Claims against Laidlaw & Company (UK) Ltd.

and Laidlaw & Company (UK) Ltd related persons, and Laidlaw & Company (UK) Ltd. hereby releases all Released Claims against

Relmada and all Relmada related persons.

Relmada Therapeutics, Inc.

Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together

with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system

(CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone

(dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER

(REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab,

REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug

designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf.

We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications

to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of

the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based

upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss,

among other things, anticipated future performance, expected product development, product potential, future business plans and

costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words

and phrases such as "expects," "anticipates," "believes," "will," "will likely result,"

"will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual

results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement,

whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict

or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein

should not be considered to be a complete list.

Berry & Company Public Relations

275 Madison Avenue, Suite 702, 7th

floor - New York, NY 10016 - Tel: 646 677 864 www.relmada.com